YAP1 and glioblastoma: While the effectiveness of drugs targeting the Hippo pathway is currently being evaluated in clinical trials, overactivation of YAP/TAZ was found to contribute to uncontrolled cell growth and tumour progression in GBM [12, 13, 14], leading to therapy resistance through, in part, the maintenance of cancer stem cell population [15].